Your browser doesn't support javascript.
loading
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin, Thomas; Dimopoulos, Meletios-Athanasios; Mikhael, Joseph; Yong, Kwee; Capra, Marcelo; Facon, Thierry; Hajek, Roman; Spicka, Ivan; Baker, Ross; Kim, Kihyun; Martinez, Gracia; Min, Chang-Ki; Pour, Ludek; Leleu, Xavier; Oriol, Albert; Koh, Youngil; Suzuki, Kenshi; Casca, France; Macé, Sandrine; Risse, Marie-Laure; Moreau, Philippe.
Afiliación
  • Martin T; Department of Hematology, University of California at San Francisco, San Francisco, CA, USA. Tom.Martin@ucsf.edu.
  • Dimopoulos MA; The National and Kapodistrian University of Athens, Athens, Greece.
  • Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
  • Yong K; Department of Haematology, University College Hospital, London, UK.
  • Capra M; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
  • Facon T; Department of Haematology, Lille University Hospital, Lille, France.
  • Hajek R; Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Spicka I; Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
  • Baker R; Perth Blood Institute, Murdoch University, Perth, Australia.
  • Kim K; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Martinez G; Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Min CK; Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm, 1402, Poitiers Cedex, France.
  • Oriol A; Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain.
  • Koh Y; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Suzuki K; Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Casca F; Ividata Life Science, Levallois-Perret, France.
  • Macé S; Sanofi, R&D, Chilly-Mazarin, France.
  • Risse ML; Sanofi, R&D, Vitry-sur-Seine, France.
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Blood Cancer J ; 13(1): 152, 2023 Sep 27.
Article en En | MEDLINE | ID: mdl-37752114
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Blood Cancer J Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Blood Cancer J Año: 2023 Tipo del documento: Article